Collectively, a clear difference exists between low-risk and high-risk MDS in terms of their immunological environment and the phenotypes of their CD4+ T cells, suggesting that high, and low-risk MDS should be considered as distinct disorders. The gene discussed is CD4; the disease is myelodysplastic syndrome.